trending Market Intelligence /marketintelligence/en/news-insights/trending/k4PZUfXS9MhFV0Q9VWkIQQ2 content esgSubNav
In This List

Japan's Hisamitsu seeks US FDA nod for schizophrenia therapy

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Japan's Hisamitsu seeks US FDA nod for schizophrenia therapy

Japan's Hisamitsu Pharmaceutical Co. Inc. and its U.S. unit Noven Pharmaceuticals Inc. submitted an application seeking U.S. Food and Drug Administration approval for schizophrenia treatment HP-3070.

Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels and behaves.

HP-3070, or asenapine maleate, is a patch placed on the skin to deliver medication into the bloodstream. The transdermal therapy was previously shown to improve symptoms of the disorder in a late-stage study.